JP2023518829A5 - - Google Patents

Info

Publication number
JP2023518829A5
JP2023518829A5 JP2022557164A JP2022557164A JP2023518829A5 JP 2023518829 A5 JP2023518829 A5 JP 2023518829A5 JP 2022557164 A JP2022557164 A JP 2022557164A JP 2022557164 A JP2022557164 A JP 2022557164A JP 2023518829 A5 JP2023518829 A5 JP 2023518829A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
effect
lowering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023497 external-priority patent/WO2021194975A1/en
Publication of JP2023518829A publication Critical patent/JP2023518829A/ja
Publication of JP2023518829A5 publication Critical patent/JP2023518829A5/ja
Pending legal-status Critical Current

Links

JP2022557164A 2020-03-25 2021-03-22 糖尿病の治療方法 Pending JP2023518829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994486P 2020-03-25 2020-03-25
US62/994,486 2020-03-25
PCT/US2021/023497 WO2021194975A1 (en) 2020-03-25 2021-03-22 Method for treating diabetes

Publications (2)

Publication Number Publication Date
JP2023518829A JP2023518829A (ja) 2023-05-08
JP2023518829A5 true JP2023518829A5 (https=) 2024-03-29

Family

ID=77890597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557164A Pending JP2023518829A (ja) 2020-03-25 2021-03-22 糖尿病の治療方法

Country Status (7)

Country Link
US (1) US12569463B2 (https=)
EP (1) EP4132505A4 (https=)
JP (1) JP2023518829A (https=)
CN (1) CN115279363A (https=)
AU (1) AU2021244313A1 (https=)
MX (1) MX2022011651A (https=)
WO (1) WO2021194975A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089572A (zh) * 2022-07-18 2022-09-23 南通大学 一种化合物olt1177在制备治疗2型糖尿病药物制剂中的应用
CN119632971A (zh) * 2024-09-10 2025-03-18 浙江大学 一种达泮舒腈的应用及药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2970485T3 (es) * 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
CN111094242B (zh) * 2017-07-24 2024-02-09 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物

Similar Documents

Publication Publication Date Title
JP2022009125A5 (https=)
JP2024540183A5 (https=)
JP2015164964A5 (https=)
JP2007514750A5 (https=)
JP2021035998A5 (https=)
ITMI952337A1 (it) Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
RU2007104095A (ru) Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств
EA015382B1 (ru) Применение рофлумиласта для лечения сахарного диабета типа 2
JP2023115271A5 (https=)
JP2023518829A5 (https=)
JP2020100623A (ja) 炎症及び疼痛の治療のための組成物及び方法
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
BR112019026029A2 (pt) Formulações farmacêuticas orais de remogliflozina
CN101642443B (zh) 单硝酸异山梨酯渗透泵型控释制剂及其制备方法
WO2008057464A2 (en) Compositions and methods for improving the bioavailability of liothyronine
WO2013026270A1 (zh) 右布洛芬左西替利嗪缓释双层片在治疗气道炎症中的用途
CN111467348A (zh) 一种n-(噻唑-2-基)-3-(哌嗪-1-基)丙酰胺类衍生物在药物制备中的应用
CN121398832A (zh) 用于药物疗法的司美格鲁肽
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
EP3220911B1 (en) Levosimendan for use as a liver protector
JP2025522146A5 (https=)
JP6698669B2 (ja) 粘膜炎の治療のための組成物及び方法
JP2024506041A5 (https=)
BRPI0713647A2 (pt) formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios
US20220233508A1 (en) Pharmaceutical composition comprising famotidine, lidocaine and melatonin